Pivonello, Rosario
Zacharieva, Sabina
Elenkova, Atanaska
Tóth, Miklós
Shimon, Ilan
Stigliano, Antonio
Badiu, Corin
Brue, Thierry
Georgescu, Carmen Emanuela
Tsagarakis, Stylianos
Cohen, Fredric
Fleseriu, Maria
Funding for this research was provided by:
Università degli Studi di Napoli Federico II
Article History
Accepted: 15 July 2022
First Online: 9 September 2022
Declarations
:
: RP reports receiving research support to Federico II University of Naples as a principal investigator for clinical trials from Corcept Therapeutics, HRA Pharma, Novartis, Recordati, and Xeris Biopharma/Strongbridge Biopharma; receiving different research support to Federico II University of Naples from Novartis and Xeris/Strongbridge; and receiving occassional consulting honoraria from Corcept Therapeutics, HRA Pharma, Novartis, Recordati, and Xeris/Strongbridge. SZ reports receiving consulting honoraria from Novartis. AE reports serving as the principal investigator/sub-investigator of clinical trials for Corcept Therapeutics and Novartis; and receiving consulting honoraria from Novartis. MT reports serving as the principal investigator of clinical trials for Corcept Therapeutics, HRA Pharma, Novartis, and Xeris/Strongbridge; serving as an occasional scientific consultant to HRA Pharma and Recordati; and receiving speaker’s fees from Medis, Novartis, and Xeris/Strongbridge. IS reports receiving research grants, consulting, and lectureship fees from Medison Pharma, Novartis International, and Pfizer. AS reports receiving no grants or consulting honoraria from pharmaceutical companies. CB reports serving as the principal investigator of research grants from Novo Nordisk and Xeris/Strongbridge; and receiving consulting honoraria from Ipsen. TB reports serving as a clinical trial investigator for Novartis and Xeris/Strongbridge; receiving research grants from Ipsen and Pfizer; and serving as an advisory board member or receiving speaker’s fees from Ipsen, Novartis, Pfizer, and Xeris/Strongbridge. CEG reports serving as the principal investigator of clinical trials for HRA Pharma and Xeris/Strongbridge. ST reports receiving research and travel grants and consulting honoraria from Novartis; and receiving consulting honoraria from Recordati. FC is a former employee of Strongbridge Biopharma/Xeris Pharma and reports receiving consulting fees from Xeris. MF reports serving as an investigator with research grants to OHSU from Novartis, Recordati, and Xeris/Strongbridge; serving as an occasional scientific consultant to HRA Pharma, Recordati, Sparrow, and Xeris/Strongbridge; and is on the Editorial Board of Pituitary.
: The study was approved by an institutional review board or independent ethics committee at each site and conducted in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice and the ethical principles of the Declaration of Helsinki.
: Written informed consent was provided by each patient to participate in the study.